FDA Publishes Its Draft Strategy Document on Innovative Manufacturing Technologies
FDA Law Blog: Biosimilars
SEPTEMBER 16, 2024
This FR Notice and draft strategy document are part of FDA’s commitment under the Prescription Drug User Fee Act (PDUFA) Reauthorization Performance Goals and Procedures for Fiscal Years 2023-2027 (PDUFA VII), wherein FDA committed to advance the use and implementation of innovative manufacturing.
Let's personalize your content